home company team news contact
Gene Logic Inc. (GLGC) OBP I, II
Gaithersburg, MD

Gene Logic is the leading provider of bioinformation products based upon the use of microarray technology for gene expression profiling of biological systems.
Human Genome Sciences, Inc. (HGSI) OBP I  
Rockville, MD

Human Genome Sciences, Inc. identifies and commercializes genes for human therapeutic development.

Exelixis, Inc. (EXEL) OBP I, II  
South San Francisco, CA

Exelixis is a drug discovery company with expertise in comparative genomics and model system genetics used to identify key members of critical disease pathways in diseases such as cancer.

Genset S.A. (GENXY) OBP I
Paris, France

Genset is the first significant French genomics company.
ACADIA Pharmaceuticals Inc. (ACAD) OBP IV
San Diego, CA

Acadia is a small molecule drug discovery and development company to identify novel chemistries focused on diseases such as Parkinson's, psychosis, chronic pain and glaucoma.

AVEO Pharmaceuticals, Inc. (AVEO) OBP IV
Cambridge, MA

AVEO is a cancer therapeutics discovery company using in vivo tumor models and focusing on tumor maintenance genes.

Cardiome Pharma Corp (CRME) OBP IV
Vancouver, British Columbia

Cardiome is a product-focused cardiovascular drug development company focused on atrial arrhythmia and congestive heart failure.

Ceres, Inc. (CERE) OBP II
Thousand Oaks, CA

Ceres is a plant genomics company identifying key genes determining seed size, quantity, and yield amounts, as well as pesticide and herbicide resistance.

Dicerna Pharmaceuticals, Inc. (DRNA) OBP V
Cambridge, MA

Dicerna Pharmaceuticals is developing novel therapeutics in multiple therapeutic areas based on Dicer substrate technology, which makes use of the RNA interference mechanism.

Enanta Pharmaceuticals, Inc. (ENTA) OBP III
Watertown, MA

Enanta Pharmaceuticals is using its cutting-edge chemistry technology and drug
discovery capabilities to create best in class small molecule drugs. The company is initially focused on building a pipeline of first generation bridged bicyclic macrolide and ketolide antibiotics to combat bacterial resistance in the treatment of respiratory tract infections (RTI) and hospital borne diseases.

ExonHit Therapeutics, S.A. (ALEHT) OBP II
Paris, France

ExonHit Therapeutics is a drug discovery and development company using analysis of RNA splicing events as the basis for target identification and lead selection.

Genetic Therapy, Inc. OBP I  
Gaithersburg, MD

Genetic Therapy was a company dedicated to bringing to market gene therapy products for the treatment of life-threatening genetic and acquired diseases. It was sold to Novartis(NVS) in 1995.

Geron Corporation (GERN) OBP I
Menlo Park, CA
Geron develops and commercializes therapeutic and diagnostic products for oncology and regenerative medicine.

Glori Energy (GLRI) OBP V
Houston, TX

Glori Energy is innovating for the next generation by servicing the upstream oil industry with breakthrough biotechnology that safely increases oil production.

Illumina, Inc. (ILMN) OBP III, IV
San Diego, CA

Illumina develops tools for large-scale analysis of genetic variations and gene function.

Inkine Pharmaceutical Company, Inc. (INKP) OBP II  
Blue Bell, PA

InKine Pharmaceutical Company, Inc. is a publicly-traded biopharmaceutical company that focuses on the diagnosis and treatment of cancer and autoimmune disease. Its products include Visicol' and Colirest'.

Inverness Medical Innovations, Inc. (IMA) OBP IV  
Waltham, MA

Inverness Medical Innovations, Inc. is developing innovative consumer OTC products focused on the self-management of diabetes, pregnancy and ovulation, as well as manufacturing and marketing a line of nutritional supplements.

Orchid BioSciences, Inc. (ORCH) OBP II  
Princeton, NJ

Orchid BioSciences is now a leading provider of products, services and technologies for single nucleotide polymorphism (SNP) scoring and genetic diversity analyses.

QuadraMed Corporation (QMDC) OBP I  
San Rafael, CA

QuadraMed develops acute care information management solutions for health care professionals.

Salix Pharmaceuticals, Ltd. (SLXP) OBP III  
Raleigh, NC

Salix Pharmaceuticals, Ltd. identifies and acquires late-stage proprietary pharmaceutical products having an existing base of safety and efficacy data in humans for the treatment of gastrointestinal disease and applies the company's regulatory, product development, and sales and marketing expertise to commercialize these products.

Santhera Pharmaceuticals AG (SANN) OBP III
(Formerly Graffinity Pharmaceuticals AG; merged with MyoContract AG to form new company, Santhera Pharmaceuticals AG)
Liestal (Basel), Switzerland and Heidelberg, Germany

Santhera focuses on the discovery, development and commercialization of small molecule drugs in the areas of neuromuscular and metabolic diseases.

Sosei Co., Ltd. (Nikkei: 4565) OBP I
Tokyo, Japan

Sosei is focused on (i) helping to expedite the commercialization of Japanese university-based technologies, (ii) effecting change in the methods of technology transfer between Japan and the U.S., and (iii) providing a reliable platform in Japan for small, innovative U.S. businesses seeking Japanese corporate partners.

Targacept, Inc. (TRGT) OBP IV
Winston-Salem, NC

Targacept, Inc. was spun out of RJ Reynolds and focuses on novel therapeutics in neurological, psychiatric and GI arenas. The company has products that focus on dementia and ulcerative colitis.

Mountain View, CA

Vivus, Inc. is a pharmaceutical company engaged in developing, acquiring and marketing innovative products to improve quality of life disorders in men and women, with a focus on sexual dysfunction.

Xencor, Inc. (XNCR) OBP V
Monrovia, CA

Xencor is a later-stage company that has successfully developed a protein engineering technology and has used that technology to develop a clinical pipeline. Xencor has partnered with leading biotech companies, including Genentech and Eli Lilly and is designing next-generation protein drug candidates with improved selectivity, efficacy and safety.